Health & Education · Basel

US regulator approves Roche's oral breast cancer pill Wilserdly for ESR1-mutated disease

The FDA approved Roche's oral giredestrant, sold as Wilserdly, together with everolimus on Monday, 16 November. A second US decision on early-stage use is expected by late November, and Roche expects sales contributions from 2027.

AI text based on reports by Neue Zürcher Zeitung, 20 Minuten, SWI swissinfo.ch and other publishers. Published . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

Basel · Switzerland
How it came to this
  1. 16 NovFDA approves Wilserdly with everolimus; Roche announces the decision late on Monday
  2. 30 NovDeadline for the FDA decision on early-stage use, per Handelsblatt
  3. 2027Roche expects Wilserdly's first full year on the US market

FDA approval and eligible patients

The US Food and Drug Administration has approved Wilserdly, the brand name for the drug giredestrant, in combination with everolimus. The approval covers patients with oestrogen receptor-positive, HER2-negative breast cancer that carries an ESR1 gene mutation and is either locally advanced or metastatic. Roche announced the decision late on Monday, 16 November. The medicine is taken as a tablet, which spares patients injections. According to a separate FDA document, the drug is meant for patients whose disease returned during or after adjuvant endocrine therapy, or progressed on at least one endocrine therapy at the metastatic stage. The prescribing information carries warnings and precautions, in particular about embryo-foetal toxicity.

Trial results and price

Roche states that the combination delayed disease progression or reduced mortality by 62% compared with standard endocrine therapy combined with everolimus. Handelsblatt describes the same result as a 62% reduction in the risk of progression or death in a phase III study. Roche puts the list price at $22,500 per month, while stressing that what patients actually pay depends on insurance coverage or public assistance schemes. RBC Capital Markets analyst Trung Huynh said the price sits roughly at the level of Eli Lilly's Inluriyo treatment, and called the approval an important first step. RBC's commentary also notes that the price is lower than that of AstraZeneca's Etcamah.

Sales expectations and analysts

Roche expects giredestrant to reach peak annual sales of more than CHF3 billion, and NZZ reports that CEO Thomas Schinecker sees the drug as having the potential to become the best-selling product in the company's history. Roche told AWP that it expects the launch to contribute to sales from next year, with 2027 as the first full year on the market. The consensus estimate of $500 to 600 million is, in Roche's words, in line with its expectations. For scale, Roche recorded revenue of CHF61.52 billion in 2025, of which CHF48 billion came from its pharmaceuticals division.

Roche revenue in 2025 by segmentCHF billion
Roche group, 2025
61.52 CHF billion
Pharmaceuticals division, 2025
48 CHF billion

Data from the article text

Zurich Cantonal Bank analyst Urban Fritsche estimates that the treatment could generate up to CHF14 billion in sales at its peak in 2033. NZZ attributes a UBS forecast of CHF4.2 billion by 2031 to the Swiss bank, while swissinfo cites the same CHF4.2 billion as the consensus forecast, so the two reports differ on the time horizon.

Second approval and early-stage use

Roche is waiting for a further FDA decision on giredestrant for early-stage breast cancer, which would widen the group of eligible patients considerably. NZZ says the US approval for that use is expected by late November at the latest, while Handelsblatt reports the FDA intends to decide by 30 November under an accelerated procedure. Roche says the two approvals together should reach 70% of all breast cancer patients. The first approval covers 10% of the patients eligible for therapy with the drug, while the second covers the much larger group of 90%. Roche has announced that it will file for approval in Europe in 2027. Handelsblatt reports that study data published at the end of 2025 showed a 30% lower risk of relapse or death in early-stage disease, and that JPMorgan analysts expect annual sales of about $5 billion if that use is approved.

Setbacks and disease background

The route to the first approval was not free of setbacks. Study data presented in March showed that the drug had failed in a trial testing it as a first therapy for advanced breast cancer, and this temporarily put heavy pressure on Roche's share price. Schinecker says giredestrant would be the first new hormonal therapy for early-stage disease in almost 25 years to show a clear advantage over existing treatments. NZZ reports that 2.3 million women are diagnosed with breast cancer each year, and puts the death toll at 670,000. Breast cancer remains the most common tumour among women.

Ask about this text

Sources and context

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar